|
ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Clinical research trials and ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer. ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer clinical trial. Human subjects frequently get the finest healthcare available for their ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Z" Clinical Trials Conditions > ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer  ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
For Condition: stage 4 non-small cell lung cancer,stage 3B non-small cell lung cancer,recurrent non-small cell lung cancer
Status: No longer recruiting
Sponsor(s): AstraZeneca ,
Synopsis: RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Details: OBJECTIVES: I. Compare the 1 year survival rate, time to worsening of disease related symptoms, and progression free survival in chemotherapy naive patients with stage IIIB or IV non-small cell lung cancer treated with one of two doses of ZD 1839 or placebo combined with gemcitabine and cisplatin. PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to one of three treatment arms. Patients receive gemcitabine and cisplatin combined with lower dose oral ZD 1839 (arm I), higher dose oral ZD 1839 (arm II), or placebo (arm III). PROJECTED ACCRUAL: A total of 1,029 patients (343 per arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven non-small cell lung cancer; Stage III disease that is not curable with surgery or radiotherapy OR Stage IV disease - Chemotherapy naive --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: See Disease Characteristics - Endocrine therapy: No concurrent systemic endocrine therapy that is known to have an effect on non-small cell lung cancer - Radiotherapy: See Disease Characteristics; Prior localized irradiation allowed - Surgery: See Disease Characteristics; Prior surgery allowed - Other: No concurrent drugs with known significant cytochrome P450 3A4 inhibitory effects (e.g., ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil) --Patient Characteristics-- - Age: 18 and over - Performance status: 0-2 - Life expectancy: Not specified - Hematopoietic: Absolute neutrophil count at least 2,000/mm3; WBC at least 4,000/mm3 - Hepatic: ALT and AST less than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if liver metastasis present); Bilirubin less than 1.25 times ULN - Renal: Creatinine less than 1.5 times ULN; Creatinine clearance greater than 60 mL/min - Cardiovascular: No evidence of severe or uncontrolled cardiovascular disease - Pulmonary: No evidence of severe or uncontrolled pulmonary disease
Total Enrollment:
Location and Contact Information:
Overall Study Official:
Patient(In the US & Canada) AstraZeneca Pharmaceuticals LP, Study Chair, AstraZeneca
AstraZeneca Pharmaceuticals LP
Wilmington, Delaware, 19850-5437
United States
Additional Information:
Study ID Numbers: CDR0000068064; ZENECA-1839IL/0014
Study Start Date: May 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006048
Other Stage 3b Non-Small Cell Lung Cancer Studies:
1. R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
2. Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy
3. Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
4. Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
5. Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Related Studies:
Other stage 3B non-small cell lung cancer Clinical Trials
Other Delaware Clinical Trials
Other Wilmington Clinical Trials
ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
